BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 12105157)

  • 21. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
    Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
    Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
    Cohen M; Adams PC; Parry G; Xiong J; Chamberlain D; Wieczorek I; Fox KA; Chesebro JH; Strain J; Keller C
    Circulation; 1994 Jan; 89(1):81-8. PubMed ID: 8281698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators.
    Circulation; 1997 Aug; 96(3):769-77. PubMed ID: 9264481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
    Yusuf S
    Am J Cardiol; 1999 Sep; 84(5A):20M-25M. PubMed ID: 10505539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers.
    Van Ryn J; Kink-Eiband M; Kuritsch I; Feifel U; Hanft G; Wallenstein G; Trummlitz G; Pairet M
    J Clin Pharmacol; 2004 Jul; 44(7):777-84. PubMed ID: 15199082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction.
    Bosch X; Marrugat J
    Cochrane Database Syst Rev; 2001; (4):CD002130. PubMed ID: 11687143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
    Huynh T; Theroux P; Snapinn S; Wan Y;
    Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators
    N Engl J Med; 1998 May; 338(21):1498-505. PubMed ID: 9599104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis.
    Dequeker J; Hawkey C; Kahan A; Steinbrück K; Alegre C; Baumelou E; Bégaud B; Isomäki H; Littlejohn G; Mau J; Papazoglou S
    Br J Rheumatol; 1998 Sep; 37(9):946-51. PubMed ID: 9783758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Selective cyclooxygenase-2 inhibitor].
    Hettich M; Thomae K
    Internist (Berl); 1997 Oct; 38(10):1007. PubMed ID: 9432492
    [No Abstract]   [Full Text] [Related]  

  • 32. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
    Sabatine MS; Cannon CP; Gibson CM; López-Sendón JL; Montalescot G; Theroux P; Claeys MJ; Cools F; Hill KA; Skene AM; McCabe CH; Braunwald E;
    N Engl J Med; 2005 Mar; 352(12):1179-89. PubMed ID: 15758000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulants in acute coronary syndromes.
    Turpie AG
    Am J Cardiol; 1999 Sep; 84(5A):2M-6M. PubMed ID: 10505536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression.
    Hyde TA; French JK; Wong CK; Straznicky IT; Whitlock RM; White HD
    Am J Cardiol; 1999 Aug; 84(4):379-85. PubMed ID: 10468072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of meloxicam (A cox-2 inhibitor) for management of postoperative endodontic pain: a double-blind placebo-controlled study.
    Nekoofar MH; Sadeghipanah M; Dehpour AR
    J Endod; 2003 Oct; 29(10):634-7. PubMed ID: 14606784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
    Schreiber TL; Macina G; McNulty A; Bunnell P; Kikel M; Miller DH; Devereux RB; Tenney R; Cowley M; Zola B
    Am J Cardiol; 1989 Oct; 64(14):840-4. PubMed ID: 2801550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.